Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.

Keymeulen B, Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L.

Blood. 2010 Feb 11;115(6):1145-55. doi: 10.1182/blood-2009-02-204875. Epub 2009 Dec 9.

2.

Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, Scieux C, Devergie A, Socié G, Ribaud P, Adès L, Ferry C, Gluckman E, Charron D, Esperou H, Toubert A, Moins-Teisserenc H.

Transplantation. 2004 Jan 15;77(1):76-84.

PMID:
14724439
3.

Time course and frequency of Epstein-Barr virus reactivation after kidney transplantation: linkage to renal allograft rejection.

Jabs WJ, Maurmann S, Wagner HJ, Müller-Steinhardt M, Steinhoff J, Fricke L.

J Infect Dis. 2004 Nov 1;190(9):1600-4. Epub 2004 Sep 30.

PMID:
15478064
4.

Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution.

Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, van Baarle D, Egeler RM, van Tol MJ, Lankester AC.

Clin Infect Dis. 2006 Jun 15;42(12):1743-8. Epub 2006 May 4.

PMID:
16705581
5.

Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Onoda H, Yatabe Y, Ito M, Miyamura K, Nagai H, Moritani S, Sugiura I, Tsushita K, Mihara H, Ohbayashi K, Iba S, Emi N, Okamoto M, Iwata S, Kimura H, Kuzushima K, Morishima Y.

Leuk Lymphoma. 2015 Apr;56(4):1072-8. doi: 10.3109/10428194.2014.938326. Epub 2014 Aug 13.

PMID:
24975317
6.

Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.

Gill H, Hwang YY, Chan TS, Pang AW, Leung AY, Tse E, Kwong YL.

J Clin Virol. 2014 Apr;59(4):255-8. doi: 10.1016/j.jcv.2014.01.005. Epub 2014 Jan 18.

PMID:
24507802
7.

EBV infection and anti-CD3 treatment for Type 1 diabetes: bad cop, good cop?

Faustman DL.

Expert Rev Clin Immunol. 2013 Feb;9(2):95-7. doi: 10.1586/eci.12.101. No abstract available.

8.

Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.

Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D.

Transplantation. 2009 Apr 27;87(8):1240-5. doi: 10.1097/TP.0b013e31819f1c49.

PMID:
19384173
9.

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W, Greil J, Albert MH, Schwinger W, Nathrath M, Schumm M, Stevanovic S, Handgretinger R, Lang P, Feuchtinger T.

J Clin Oncol. 2013 Jan 1;31(1):39-48. doi: 10.1200/JCO.2011.39.8495. Epub 2012 Nov 19.

PMID:
23169501
10.

Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.

Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.

Transplantation. 2010 Sep 15;90(5):564-70. doi: 10.1097/TP.0b013e3181e7a3bf.

PMID:
20555307
11.

Distribution and phenotype of Epstein-Barr virus-infected cells in human pharyngeal tonsils.

Hudnall SD, Ge Y, Wei L, Yang NP, Wang HQ, Chen T.

Mod Pathol. 2005 Apr;18(4):519-27.

12.

Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.

Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.

Clin Transplant. 2013 Jul-Aug;27(4):E491-7. doi: 10.1111/ctr.12172. Epub 2013 Jun 19.

PMID:
23781897
13.

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.

Comoli P, Labirio M, Basso S, Baldanti F, Grossi P, Furione M, Viganò M, Fiocchi R, Rossi G, Ginevri F, Gridelli B, Moretta A, Montagna D, Locatelli F, Gerna G, Maccario R.

Blood. 2002 Apr 1;99(7):2592-8.

14.

Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring.

Wakabayashi S, Ohashi K, Hanajiri R, Kobayashi T, Yamashita T, Akiyama H, Sakamaki H.

Intern Med. 2010;49(10):931-5. Epub 2010 May 14.

15.

Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.

Choquet S, Varnous S, Deback C, Golmard JL, Leblond V.

Am J Transplant. 2014 Apr;14(4):857-66. doi: 10.1111/ajt.12640. Epub 2014 Feb 19.

16.

B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.

Dolcetti R.

Autoimmun Rev. 2007 Dec;7(2):96-101. Epub 2007 Mar 26. Review.

PMID:
18035317
17.

Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.

Sato T, Fujieda M, Maeda A, Tanaka E, Miyamura M, Chikamoto H, Hisano M, Akioka Y, Ishiura Y, Dohno S, Hattori M, Wakiguchi H.

Clin Nephrol. 2008 Nov;70(5):393-403.

PMID:
19000539
18.

Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.

Bakker NA, Verschuuren EA, Erasmus ME, Hepkema BG, Veeger NJ, Kallenberg CG, van der Bij W.

Transplantation. 2007 Feb 27;83(4):433-8.

PMID:
17318076
19.

Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?

Savani BN, Pohlmann PR, Jagasia M, Chinratanalab W, Kassim A, Engelhardt B, Greer J, Schuening F, Goodman S.

Blood. 2009 Jun 11;113(24):6263-4. doi: 10.1182/blood-2009-04-213892. No abstract available.

20.

[Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].

Lu Y, Wu T, Cao XY, Wang JB, Sun Y, Zhao YL, DA WM, Ji SQ, Tong CR, Lu DP.

Zhonghua Nei Ke Za Zhi. 2011 May;50(5):383-7. Chinese.

PMID:
21624219

Supplemental Content

Support Center